Literature DB >> 9127414

A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children.

J M Chamberlain1, M A Altieri, C Futterman, G M Young, D W Ochsenschlager, Y Waisman.   

Abstract

OBJECTIVE: To compare treatment of ongoing seizures using intramuscular (IM) midazolam versus intravenous (IV) diazepam.
DESIGN: Controlled clinical trial. PATIENTS: Children with motor seizures of at least 10 minutes' duration. MAIN OUTCOME MEASURES: Time to cessation of seizures.
RESULTS: Twenty-four patients were enrolled (13 midazolam, 11 diazepam). Initial treatment with either midazolam or diazepam was successful in 22 of the 24 patients. One patient in each group failed therapy and eventually required endotracheal intubation and general anesthesia for convulsive status epilepticus lasting more than one hour. Patients in the midazolam group received medication sooner (3.3 +/- 2.0 vs 7.8 +/- 3.2 minutes, P = 0.001) and had more rapid cessation of their seizures (7.8 +/- 4.1 vs 11.2 +/- 3.6, P = 0.047) than patients randomized to receive diazepam.
CONCLUSIONS: IM midazolam is an effective anticonvulsant for children with motor seizures. Compared to IV diazepam, IM midazolam results in more rapid cessation of seizures because of more rapid administration. The IM route of administration may be particularly useful in physicians' offices, in the prehospital setting, and for children with difficult IV access.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9127414     DOI: 10.1097/00006565-199704000-00002

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  32 in total

Review 1.  Status epilepticus: an evidence based guide.

Authors:  Matthew Walker
Journal:  BMJ       Date:  2005-09-24

Review 2.  Continuous electroencephalogram monitoring in critically ill patients.

Authors:  Nathalie Jette; Lawrence J Hirsch
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

3.  Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.

Authors:  Tracy Glauser; Shlomo Shinnar; David Gloss; Brian Alldredge; Ravindra Arya; Jacquelyn Bainbridge; Mary Bare; Thomas Bleck; W Edwin Dodson; Lisa Garrity; Andy Jagoda; Daniel Lowenstein; John Pellock; James Riviello; Edward Sloan; David M Treiman
Journal:  Epilepsy Curr       Date:  2016 Jan-Feb       Impact factor: 7.500

4.  Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis.

Authors:  Jason McMullan; Comilla Sasson; Arthur Pancioli; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-06       Impact factor: 3.451

5.  Efficacy of nonvenous medications for acute convulsive seizures: A network meta-analysis.

Authors:  Ravindra Arya; Harsh Kothari; Zongjun Zhang; Baoguang Han; Paul S Horn; Tracy A Glauser
Journal:  Neurology       Date:  2015-10-28       Impact factor: 9.910

6.  Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus.

Authors:  James M Chamberlain; Edmund V Capparelli; Kathleen M Brown; Cheryl W Vance; Kathleen Lillis; Prashant Mahajan; Richard Lichenstein; Rachel M Stanley; Colleen O Davis; Stephen Gordon; Jill M Baren; John N van den Anker
Journal:  J Pediatr       Date:  2011-11-01       Impact factor: 4.406

7.  Intramuscular midazolam vs intravenous diazepam for acute seizures.

Authors:  Ira Shah; C T Deshmukh
Journal:  Indian J Pediatr       Date:  2005-08       Impact factor: 1.967

Review 8.  Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

9.  Prospective study of new-onset seizures presenting as status epilepticus in childhood.

Authors:  R K Singh; S Stephens; M M Berl; T Chang; K Brown; L G Vezina; W D Gaillard
Journal:  Neurology       Date:  2010-01-20       Impact factor: 9.910

Review 10.  New Non-Intravenous Routes for Benzodiazepines in Epilepsy: A Clinician Perspective.

Authors:  Marco Mula
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.